HLS Therapeutics Inc.
HLS
Peringkat dalam Saham
#21945
HLS Therapeutics Inc. operates as a specialized pharmaceutical firm,... HLS Therapeutics Inc. operates as a specialized pharmaceutical firm, concentrating on the acquisition and commercialization of medicinal products, primarily within the niche central nervous system (CNS) and cardiovascular (CV) sectors. Its reach extends across Canada, the United States, and international markets. The company's core product lineup includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsule formulation; and PERSERIS, an injectable risperidone product for treating schizophrenia. Additionally, HLS offers MyCare psychiatry laboratory assays and MyCare Insite tests for point-of-care therapeutic drug-level monitoring. Furthermore, the company possesses U.S. marketing privileges for Absorica, a commercial-stage dermatology solution, and Canadian rights for Trinomia, a cardiovascular therapeutic. It also manages a portfolio of royalty interests from four distinct healthcare products. Founded in 2018, HLS Therapeutics Inc. is based in Etobicoke, Canada.
Harga Saham
$3.01
Terakhir disinkronkan: 2026-10-19
Kapitalisasi Pasar
$92.97M
Perubahan (1 hari)
0.86%
Perubahan (1 tahun)
-25.24%
Negara
CA
Perdagangan HLS Therapeutics Inc. (HLS)
Kategori
Healthcare
Riwayat dividen untuk HLS Therapeutics Inc. (HLS)
Saham HLS Therapeutics Inc. (simbol: HLS) telah membayar total 0 dividen.
Total semua dividen (disesuaikan dengan stock split): 0.00
Imbal hasil dividen (TTM): 0
Total semua dividen (disesuaikan dengan stock split): 0.00
Imbal hasil dividen (TTM): 0
Pembayaran dividen untuk HLS Therapeutics Inc. (HLS) dari 2026 hingga 2026
Pembayaran dividen tahunan
| Tahun | Dividen (disesuaikan dengan stock split) | Mengubah |
|---|---|---|
| Tidak cukup data untuk tanggal yang disediakan. | ||
Daftar semua pembayaran dividen
| Tahun | Dividen | Mengubah |
|---|---|---|
| Tidak cukup data untuk tanggal yang disediakan. | ||
Pembayaran dividen untuk perusahaan sejenis atau pesaing
| Perusahaan | Jumlah pembayaran dividen | Negara |
|---|---|---|
| 0.00% |
DE
|
|
| 0.00% |
DE
|
|
| 0.00% |
JP
|
|
| 0.00% |
CH
|
|
| 38.00% |
IN
|
